Intravenous immunoglobulins as therapeutic agents

E. R. Stiehm, E. Ashida, Kwang Sik Kim, D. J. Winston, A. Haas, R. P. Gale

Research output: Contribution to journalArticle

Abstract

Intravenous immunoglobulins are stable monomeric pooled human IgG preparations for therapeutic use. Three intravenous immunoglobulins licensed in the United States are generally therapeutically equivalent. Intravenous immunoglobulin is the preferred agent for replacement therapy for most patients with primary or secondary antibody immunodeficiency because of the rapidity and ease of giving large quantities of IgG, even by self-administration. Disadvantages of intravenous immunoglobulins include frequent (approximately 10%) but usually not serious side effects, the need for venous access (often difficult in infants and young children), and high cost. Intravenous immunoglobulins are also beneficial in the prevention of certain viral infections, such as cytomegalovirus pneumonia and varicella; they may also have a synergistic effect with antibiotics in certain bacterial diseases. Intravenous immunoglobulin has also been used successfully in the management of idiopathic thrombocytopenia purpura, Kawasaki disease, and certain autoimmune diseases. Intravenous immunoglobulin may also be of use in certain high-risk and premature newborns.

Original languageEnglish (US)
Pages (from-to)367-382
Number of pages16
JournalAnnals of Internal Medicine
Volume107
Issue number3
StatePublished - 1987
Externally publishedYes

Fingerprint

Intravenous Immunoglobulins
Therapeutics
Immunoglobulin G
Mucocutaneous Lymph Node Syndrome
Self Administration
Purpura
Chickenpox
Therapeutic Uses
Virus Diseases
Cytomegalovirus
Thrombocytopenia
Autoimmune Diseases
Pneumonia
Newborn Infant
Anti-Bacterial Agents
Costs and Cost Analysis
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stiehm, E. R., Ashida, E., Kim, K. S., Winston, D. J., Haas, A., & Gale, R. P. (1987). Intravenous immunoglobulins as therapeutic agents. Annals of Internal Medicine, 107(3), 367-382.

Intravenous immunoglobulins as therapeutic agents. / Stiehm, E. R.; Ashida, E.; Kim, Kwang Sik; Winston, D. J.; Haas, A.; Gale, R. P.

In: Annals of Internal Medicine, Vol. 107, No. 3, 1987, p. 367-382.

Research output: Contribution to journalArticle

Stiehm, ER, Ashida, E, Kim, KS, Winston, DJ, Haas, A & Gale, RP 1987, 'Intravenous immunoglobulins as therapeutic agents', Annals of Internal Medicine, vol. 107, no. 3, pp. 367-382.
Stiehm ER, Ashida E, Kim KS, Winston DJ, Haas A, Gale RP. Intravenous immunoglobulins as therapeutic agents. Annals of Internal Medicine. 1987;107(3):367-382.
Stiehm, E. R. ; Ashida, E. ; Kim, Kwang Sik ; Winston, D. J. ; Haas, A. ; Gale, R. P. / Intravenous immunoglobulins as therapeutic agents. In: Annals of Internal Medicine. 1987 ; Vol. 107, No. 3. pp. 367-382.
@article{9f7c4de632d549aa98f5429b00f80a1b,
title = "Intravenous immunoglobulins as therapeutic agents",
abstract = "Intravenous immunoglobulins are stable monomeric pooled human IgG preparations for therapeutic use. Three intravenous immunoglobulins licensed in the United States are generally therapeutically equivalent. Intravenous immunoglobulin is the preferred agent for replacement therapy for most patients with primary or secondary antibody immunodeficiency because of the rapidity and ease of giving large quantities of IgG, even by self-administration. Disadvantages of intravenous immunoglobulins include frequent (approximately 10{\%}) but usually not serious side effects, the need for venous access (often difficult in infants and young children), and high cost. Intravenous immunoglobulins are also beneficial in the prevention of certain viral infections, such as cytomegalovirus pneumonia and varicella; they may also have a synergistic effect with antibiotics in certain bacterial diseases. Intravenous immunoglobulin has also been used successfully in the management of idiopathic thrombocytopenia purpura, Kawasaki disease, and certain autoimmune diseases. Intravenous immunoglobulin may also be of use in certain high-risk and premature newborns.",
author = "Stiehm, {E. R.} and E. Ashida and Kim, {Kwang Sik} and Winston, {D. J.} and A. Haas and Gale, {R. P.}",
year = "1987",
language = "English (US)",
volume = "107",
pages = "367--382",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Intravenous immunoglobulins as therapeutic agents

AU - Stiehm, E. R.

AU - Ashida, E.

AU - Kim, Kwang Sik

AU - Winston, D. J.

AU - Haas, A.

AU - Gale, R. P.

PY - 1987

Y1 - 1987

N2 - Intravenous immunoglobulins are stable monomeric pooled human IgG preparations for therapeutic use. Three intravenous immunoglobulins licensed in the United States are generally therapeutically equivalent. Intravenous immunoglobulin is the preferred agent for replacement therapy for most patients with primary or secondary antibody immunodeficiency because of the rapidity and ease of giving large quantities of IgG, even by self-administration. Disadvantages of intravenous immunoglobulins include frequent (approximately 10%) but usually not serious side effects, the need for venous access (often difficult in infants and young children), and high cost. Intravenous immunoglobulins are also beneficial in the prevention of certain viral infections, such as cytomegalovirus pneumonia and varicella; they may also have a synergistic effect with antibiotics in certain bacterial diseases. Intravenous immunoglobulin has also been used successfully in the management of idiopathic thrombocytopenia purpura, Kawasaki disease, and certain autoimmune diseases. Intravenous immunoglobulin may also be of use in certain high-risk and premature newborns.

AB - Intravenous immunoglobulins are stable monomeric pooled human IgG preparations for therapeutic use. Three intravenous immunoglobulins licensed in the United States are generally therapeutically equivalent. Intravenous immunoglobulin is the preferred agent for replacement therapy for most patients with primary or secondary antibody immunodeficiency because of the rapidity and ease of giving large quantities of IgG, even by self-administration. Disadvantages of intravenous immunoglobulins include frequent (approximately 10%) but usually not serious side effects, the need for venous access (often difficult in infants and young children), and high cost. Intravenous immunoglobulins are also beneficial in the prevention of certain viral infections, such as cytomegalovirus pneumonia and varicella; they may also have a synergistic effect with antibiotics in certain bacterial diseases. Intravenous immunoglobulin has also been used successfully in the management of idiopathic thrombocytopenia purpura, Kawasaki disease, and certain autoimmune diseases. Intravenous immunoglobulin may also be of use in certain high-risk and premature newborns.

UR - http://www.scopus.com/inward/record.url?scp=0023255415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023255415&partnerID=8YFLogxK

M3 - Article

C2 - 3304051

AN - SCOPUS:0023255415

VL - 107

SP - 367

EP - 382

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -